Moving forward, Stone & Magnanini will be prosecuting several significant False Claims Act cases, including a recently unsealed case against Forest Laboratories, Inc. for paying kickbacks and off-label marketing of the psychiatric drugs Lexapro and Celexa.
“We are excited about this opportunity to grow our profitable False Claims Act practice and to continue to build our complex litigation practice. Stone & Magnanini is well positioned to take on any case we believe has merit — free of the conflicts inherent in larger firms representing institutional clients,” stated Stone in making the public announcement.
In addition to its False Claims Acts practice, Stone & Magnanini will continue to represent clients in other complex litigations, including antitrust, securities, white collar criminal defenses, corporate compliance, internal investigations and appellate matters.
SOURCE Stone & Magnanini LLP